News

Jefferies Maintains Buy Rating on Gilead Sciences (GILD), Cites Robust Pipeline
Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...
A new shot prevents HIV—and breathes new life into a stagnant biotech
Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...